Canon Medical Receives FDA Clearance for Compressed SPEEDER Technology for 1.5T MR, Enabling Reduced Scan Times

New Software Version for Vantage Orian 1.5T Also Offers Cybersecurity Solutions to Protect Patient Data

June 15, 2020

Canon Medical notes that hospitals and institutions are continually looking for ways to improve diagnostic imaging throughput, especially in today’s environment where disinfection of systems and rooms in between patients is crucial.

Canon Medical says now, with the newly FDA-cleared Compressed SPEEDER technology for Canon Medical’s Vantage Orian 1.5T MR system, clinicians can speed up MRI scan times by reconstructing full resolution images from under-sampled data through iterative reconstruction, improving throughput and allowing for substantial time in between exams to help clean or disinfect the scanner if necessary.

Scan times for MRIs have historically been a challenge. To reduce acquisition times, Compressed SPEEDER, also available on the Vantage Galan 3T MR system, supports image acceleration and can be used to avoid unfolding error artifacts sometimes seen with standard parallel imaging, or can achieve higher resolution in 2D Fast Spin Echo (FSE) acquisitions. Reduced scan times also enhance patient comfort, which in turn may enable higher quality images by mitigating patient movement caused by patient discomfort during long scans.

Compressed SPEEDER is included in an all-new new version of M-Power software available for the Vantage Orian 1.5T, which also comes standard with Windows 10 and embedded cybersecurity solutions from Canon Medical. Patient data is kept secure with continuous patches and updates from Microsoft, as well as whitelisting functions, which give clinicians access only to applications and processes which have been authorized.

“In MR imaging, shortening scan times is vastly important for both the patient and physician. At Canon Medical, our priority is to support our customers and their patients by providing them with timely advancements that can impact their outcomes and workflow,” said Jonathan Furuyama, managing director, MR Business Unit, Canon Medical Systems USA, Inc. “With the help of Compressed SPEEDER along with Windows 10 on the Vantage Orian 1.5T MR system, healthcare providers can offer a quick, comfortable and safe experience for their patients.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy